Rheumatoid arthritis: Developing new oral targeted therapies for RA can be challenging
Nature Reviews Rheumatology 11, 4 (2015).
doi:10.1038/nrrheum.2014.187
Author: Roy M. Fleischmann
The positive results of the phase II programme of fostamatinib, developed to target the spleen tyrosine kinase pathway in rheumatoid arthritis (RA), have not been replicated in phase III. What implications might the results have for the development of other oral inhibitors of intracellular kinases in the treatment of RA?
Source: Nature Reviews Rheumatology - Category: Rheumatology Authors: Roy M. Fleischmann Tags: News and Views Source Type: research